These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32978304)

  • 1. SARS-CoV-2 challenge studies: ethics and risk minimisation.
    Bull S; Jamrozik E; Binik A; Parker MJ
    J Med Ethics; 2020 Sep; 47(12):e79. PubMed ID: 32978304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronavirus Human Infection Challenge Studies: Assessing Potential Benefits and Risks.
    Jamrozik E; Heriot GS; Selgelid MJ
    J Bioeth Inq; 2020 Dec; 17(4):709-715. PubMed ID: 32840856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virtue ethics and the unsettled ethical questions in controlled human infection studies.
    Poomkudy JT; Shah SK
    Bioethics; 2024 Jun; ():. PubMed ID: 38881371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical issues surrounding controlled human infection challenge studies in endemic low-and middle-income countries.
    Jamrozik E; Selgelid MJ
    Bioethics; 2020 Oct; 34(8):797-808. PubMed ID: 32862482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. So much at stake: Ethical tradeoffs in accelerating SARSCoV-2 vaccine development.
    Grady C; Shah S; Miller F; Danis M; Nicolini M; Ochoa J; Taylor H; Wendler D; Rid A
    Vaccine; 2020 Sep; 38(41):6381-6387. PubMed ID: 32826103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled human infection with SARS-CoV-2 to study COVID-19 vaccines and treatments: bioethics in Utopia.
    Holm S
    J Med Ethics; 2020 Sep; 46(9):569-573. PubMed ID: 32616623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.
    Jamrozik E; Littler K; Bull S; Emerson C; Kang G; Kapulu M; Rey E; Saenz C; Shah S; Smith PG; Upshur R; Weijer C; Selgelid MJ;
    Vaccine; 2021 Jan; 39(4):633-640. PubMed ID: 33341309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical guidelines for deliberately infecting volunteers with COVID-19.
    Richards AD
    J Med Ethics; 2020 Aug; 46(8):502-504. PubMed ID: 32461245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody tests for identification of current and past infection with SARS-CoV-2.
    Fox T; Geppert J; Dinnes J; Scandrett K; Bigio J; Sulis G; Hettiarachchi D; Mathangasinghe Y; Weeratunga P; Wickramasinghe D; Bergman H; Buckley BS; Probyn K; Sguassero Y; Davenport C; Cunningham J; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Struyf T; Van den Bruel A; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD013652. PubMed ID: 36394900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethics review of COVID-19 human challenge studies: A joint HRA/WHO workshop.
    Williams E; Craig K; Chiu C; Davies H; Ellis S; Emerson C; Jamrozik E; Jefford M; Kang G; Kapulu M; Kolstoe SE; Littler K; Lockett A; Elena Rey ; Messer J; McShane H; Saenz C; Selgelid MJ; Shah S; Smith PG; Yamazaki N
    Vaccine; 2022 Jun; 40(26):3484-3489. PubMed ID: 35210119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 vaccine development: Time to consider SARS-CoV-2 challenge studies?
    Schaefer GO; Tam CC; Savulescu J; Voo TC
    Vaccine; 2020 Jul; 38(33):5085-5088. PubMed ID: 32540271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.
    Dinnes J; Sharma P; Berhane S; van Wyk SS; Nyaaba N; Domen J; Taylor M; Cunningham J; Davenport C; Dittrich S; Emperador D; Hooft L; Leeflang MM; McInnes MD; Spijker R; Verbakel JY; Takwoingi Y; Taylor-Phillips S; Van den Bruel A; Deeks JJ;
    Cochrane Database Syst Rev; 2022 Jul; 7(7):CD013705. PubMed ID: 35866452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting Ethical Payment in Human Infection Challenge Studies.
    Lynch HF; Darton TC; Levy J; McCormick F; Ogbogu U; Payne RO; Roth AE; Shah AJ; Smiley T; Largent EA
    Am J Bioeth; 2021 Mar; 21(3):11-31. PubMed ID: 33541252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 vaccines: ethical framework concerning human challenge studies.
    Calina D; Hartung T; Docea AO; Spandidos DA; Egorov AM; Shtilman MI; Carvalho F; Tsatsakis A
    Daru; 2020 Dec; 28(2):807-812. PubMed ID: 32851596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccine testing and trials in the pediatric population: biologic, ethical, research, and implementation challenges.
    Cooper DM; Afghani B; Byington CL; Cunningham CK; Golub S; Lu KD; Radom-Aizik S; Ross LF; Singh J; Smoyer WE; Lucas CT; Tunney J; Zaldivar F; Ulloa ER
    Pediatr Res; 2021 Nov; 90(5):966-970. PubMed ID: 33627824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reexamining the categorical exclusion of pediatric participants from controlled human infection trials.
    Murphy SC; Duenas DM; Richie TL; Shah SK
    Bioethics; 2020 Oct; 34(8):785-796. PubMed ID: 32715497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.